Nine of ten quarters produced negative free cash flow totaling roughly $252M, with a -39.8% FCF margin in 2026Q2 and a cumulative $87M gap between $160.6M of net losses and $247.5M of operating cash outflow suggesting cash burn is running ahead of reported earnings.
Entrada Therapeutics, Inc. (TRDA) cash flow statement — 7-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Cash from Operations | -136.32M | -128.51M | -41.56M | 139.8M | -93.79M | -50.86M | -25.57M | -10.8M |
| Operating CF Margin % | - | -505.53% | -19.72% | 108.36% | - | - | - | - |
| Operating CF Growth % | -26.09% | -209.24% | -129.73% | 249.07% | -84.39% | -98.91% | -136.74% | - |
| Net Income | -161.39M | -143.75M | 65.63M | -6.68M | -94.62M | -51.16M | -26.52M | -5.1M |
| Depreciation & Amortization | -469K | 4.1M | 3.77M | 2.84M | 1.9M | 1.12M | 326K | 104K |
| Stock-Based Compensation | 19.03M | 19.61M | 17.91M | 13.11M | 9.89M | 2.53M | 325K | 294K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.78M | -3.67M | -10.02M | -5.78M | 151K | 74K | 20K | -6.27M |
| Working Capital Changes | 4.72M | -4.8M | -118.85M | 136.31M | -11.11M | -3.42M | 282K | 174K |
| Change in Receivables | 19K | 2.5M | 2.2M | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.7M | -1.8M | 991K | -2.81M | 5.29M | -715K | 631K | 367K |
| Cash from Investing | 153.98M | 116.81M | -27.8M | -138.4M | -148.65M | -4.58M | -2.32M | -630K |
| Capital Expenditures | -9K | -1.04M | -3.16M | -5.61M | -2.89M | -4.58M | -2.32M | -630K |
| CapEx % of Revenue | 0.23% | 4.09% | 1.5% | 4.35% | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 642K | 887K | 102.96M | 21.04M | 479K | 307.46M | 50.09M | 38K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 642K | 887K | 99.61M | 19.41M | 479K | 306.52M | 49.84M | 38K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 3.36M | 1.63M | 0 | 939K | 247K | 0 |
| Net Change in Cash | 18.29M | -10.82M | 33.61M | 22.45M | -245.91M | 252.02M | 22.2M | 16.84M |
| Free Cash Flow | -136.33M | -129.55M | -44.72M | 134.19M | -96.67M | -55.44M | -27.89M | -11.43M |
| FCF Margin % | -3428.06% | -509.63% | -21.21% | 104.01% | - | - | - | - |
| FCF Growth % | -5.04% | -189.73% | -133.32% | 238.81% | -74.37% | -98.8% | -143.97% | - |
| FCF per Share | -3.22 | -3.13 | -1.15 | 4.06 | -3.09 | -1.78 | -0.89 | -10.91 |
| FCF Conversion (FCF/Net Income) | 0.84x | 0.89x | -0.63x | -20.91x | 0.99x | 0.99x | 0.96x | 2.32x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 4.62M | 14.72M | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying TRDA stock.
Entrada Therapeutics, Inc. (TRDA) generated $-128.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Entrada Therapeutics, Inc. (TRDA) reported negative free cash flow of $129.6M in 2025, indicating capital requirements exceeded cash from operations.
Entrada Therapeutics, Inc. (TRDA) spent $1.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Cash burn outpacing reported earnings
Metrics are mathematically derived from official filings.
Earnings and Cash Flow Diverge
Entrada's operating cash flow diverged sharply from reported earnings in 2024Q4, when a $1.1M net income coincided with a $31.6M cash outflow, an OCF/NI ratio of -27.94, according to the company's cash flow statements, underscoring that reported profitability has never translated into cash generation.
The OCF/NI ratio has swung from 2.22 in 2025Q1, where a $17.3M net loss met a $38.5M operating outflow, to 0.83 in 2026Q2, so the relationship between earnings and cash has never stabilized enough to treat either measure as a reliable anchor. Because cumulative operating cash outflow has run well ahead of cumulative reported losses, the income statement appears to be a poor proxy for the actual cash economics of the business.
Burn Persists Despite Revenue Collapse
Across the ten quarters presented, Entrada's free cash flow was negative in nine periods totaling roughly $252M of outflow, with the latest quarter showing a -39.8% FCF margin on an immaterial top line, as disclosed in its quarterly cash flow filings.
The burn has held in a $28M to $42M per quarter band since 2024Q3 even as revenue collapsed from $94.7M to under $1M, implying the outflow is overwhelmingly fixed R&D and SG&A spend rather than variable cost tied to commercial activity. With revenue now negligible, the FCF margin ratio has lost analytical value; the meaningful signal is the absolute quarterly burn and whether it is compressing, which it shows no clear sign of doing.
Working Capital Drives OCF Volatility
Working capital consumed $51.6M in 2024Q1 and $35.9M in 2024Q4 before swinging to a $10.2M source in 2025Q3, a reversal pattern that has materially shaped reported operating cash flow, per Entrada's consolidated statements of cash flows.
The magnitude of these swings often exceeds the underlying operating loss in the same quarter, suggesting working capital timing rather than earnings performance is the dominant driver of quarter-to-quarter OCF variation. For a business whose revenue is now immaterial, such large and directionally inconsistent working capital movements warrant further investigation into which balance sheet accounts are generating them, since they obscure the true operating burn.
Cumulative Cash Gap Exceeds Losses
Over the ten quarters presented, Entrada accumulated $160.6M of net losses against $247.5M of operating cash outflow, a cumulative gap of about $87M in which cash consumption has run materially ahead of reported earnings, based on Entrada's reported figures.
Excluding the two profitable periods of 2024Q2 and 2024Q4, every quarter shows both negative earnings and negative operating cash flow, with no visible trend toward convergence between the two lines. This persistent shortfall suggests that accruals, working capital movements and non-operating items may have systematically flattered cumulative reported performance relative to realized cash, which investors should weigh before relying on net income as a value measure.
Non-Cash Cushions Mask True Cost
Stock-based compensation added back to cash flow reached $9.9M in 2026Q2 versus $3.7M in 2024Q1, totaling roughly $52M across the period, while depreciation exceeded capital expenditure in most quarters, meaning reported operating outflows benefit from non-cash cushions.
That $52M of SBC never appears as an operating cash outflow, yet represents real dilution to continuing shareholders, so the reported OCF line simultaneously understates the economic cost of compensation and overstates the cash burden borne by owners. Depreciation running ahead of capex further indicates the existing asset base is being consumed rather than renewed, an effect entirely invisible in the headline OCF figure and one that may not be sustainable indefinitely.
Minimal Reinvestment Amid Heavy Operating Burn
Entrada's capital expenditure remained at or below $1.1M in every quarter of the period, dwarfed by quarterly depreciation running near $0.8M to $1.6M in most periods, as reported in its cash flow statements, signaling a business that is not reinvesting in productive assets.
Capex of this scale against quarterly operating losses near $40M means capital discipline is effectively irrelevant to the cash trajectory, which is set almost entirely by operating expense decisions rather than investment choices. The absence of meaningful reinvestment also implies there is little new asset base to generate future depreciation shelter, and investors should not expect capex to become a material cash user absent a strategic shift.